Arlt et al. reported that constitutive NF-κB activity confers resistance to gemcitabine-induced cell death in pancreatic cancer, while inhibition of NF-κB strongly diminishes gemcitabine resistance [5]. Here, NFKB1 is linked to pancreatic neoplasm.